A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
Clinical Trials Arena on MSN9d
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpointsAll the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.
Including patients who used topical rescue medication, almost half of patients treated with rocatinlimab met the 75% response ...
Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...
Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE ...
The IGNITE study, which evaluated two dose strengths of rocatinlimab, met its co-primary endpoints and all key secondary endpoints, achieving statistical significance for both rocatinlimab dose ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback